Various Aspects of a Gene Editing System-CRISPR-Cas9

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Dec 19

PMID 33339441

Citations 44

Authors

Edyta Janik

Marcin Niemcewicz

Michal Ceremuga

Lukasz Krzowski

Joanna Saluk-Bijak

Michal Bijak

Affiliations

Soon will be listed here.

Abstract

The discovery of clustered, regularly interspaced short palindromic repeats (CRISPR) and their cooperation with CRISPR-associated (Cas) genes is one of the greatest advances of the century and has marked their application as a powerful genome engineering tool. The CRISPR-Cas system was discovered as a part of the adaptive immune system in bacteria and archaea to defend from plasmids and phages. CRISPR has been found to be an advanced alternative to zinc-finger nucleases (ZFN) and transcription activator-like effector nucleases (TALEN) for gene editing and regulation, as the CRISPR-Cas9 protein remains the same for various gene targets and just a short guide RNA sequence needs to be altered to redirect the site-specific cleavage. Due to its high efficiency and precision, the Cas9 protein derived from the type II CRISPR system has been found to have applications in many fields of science. Although CRISPR-Cas9 allows easy genome editing and has a number of benefits, we should not ignore the important ethical and biosafety issues. Moreover, any tool that has great potential and offers significant capabilities carries a level of risk of being used for non-legal purposes. In this review, we present a brief history and mechanism of the CRISPR-Cas9 system. We also describe on the applications of this technology in gene regulation and genome editing; the treatment of cancer and other diseases; and limitations and concerns of the use of CRISPR-Cas9.

Citing Articles

Exploring the dual roles of sec-dependent effectors from Candidatus Liberibacter asiaticus in immunity of citrus plants.

Li X, Zhou Y, Chen H, Guo Z, Zhang J, Chen W Plant Cell Rep. 2025; 44(2):38.

PMID: 39864032 DOI: 10.1007/s00299-024-03397-3.

CRISPR-Cas9 in Cardiovascular Medicine: Unlocking New Potential for Treatment.

Bonowicz K, Jerka D, Piekarska K, Olagbaju J, Stapleton L, Shobowale M Cells. 2025; 14(2).

PMID: 39851560 PMC: 11763404. DOI: 10.3390/cells14020131.

Current Knowledge on CRISPR Strategies Against Antimicrobial-Resistant Bacteria.

de la Fuente Tagarro C, Martin-Gonzalez D, De Lucas A, Bordel S, Santos-Beneit F Antibiotics (Basel). 2025; 13(12.

PMID: 39766530 PMC: 11672446. DOI: 10.3390/antibiotics13121141.

Gene therapy as an emerging treatment for mutation-induced autism spectrum disorders.

Ghosh A, Nadella N, Monaghan-Nichols A, Chu X Fundam Res. 2024; 4(6):1401-1404.

PMID: 39734530 PMC: 11670658. DOI: 10.1016/j.fmre.2023.02.004.

New insights into the role of mitophagy related gene affecting the metastasis of osteosarcoma through scRNA-seq and CRISPR-Cas9 genome editing.

Zheng S, Luo M, Huang H, Huang X, Peng Z, Zheng S Cell Commun Signal. 2024; 22(1):592.

PMID: 39696352 PMC: 11657588. DOI: 10.1186/s12964-024-01989-w.

References

Kumaran N, Moore A, Weleber R, Michaelides M . Leber congenital amaurosis/early-onset severe retinal dystrophy: clinical features, molecular genetics and therapeutic interventions. Br J Ophthalmol. 2017; 101(9):1147-1154. PMC: 5574398. DOI: 10.1136/bjophthalmol-2016-309975. View

Musunuru K . The Hope and Hype of CRISPR-Cas9 Genome Editing: A Review. JAMA Cardiol. 2017; 2(8):914-919. DOI: 10.1001/jamacardio.2017.1713. View

Makarova K, Wolf Y, Iranzo J, Shmakov S, Alkhnbashi O, Brouns S . Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants. Nat Rev Microbiol. 2019; 18(2):67-83. PMC: 8905525. DOI: 10.1038/s41579-019-0299-x. View

Liang P, Xu Y, Zhang X, Ding C, Huang R, Zhang Z . CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell. 2015; 6(5):363-372. PMC: 4417674. DOI: 10.1007/s13238-015-0153-5. View

Kang Y, Kwon K, Ryu J, Lee H, Park C, Chung H . Nonviral Genome Editing Based on a Polymer-Derivatized CRISPR Nanocomplex for Targeting Bacterial Pathogens and Antibiotic Resistance. Bioconjug Chem. 2017; 28(4):957-967. DOI: 10.1021/acs.bioconjchem.6b00676. View

Gao C . The future of CRISPR technologies in agriculture. Nat Rev Mol Cell Biol. 2018; 19(5):275-276. DOI: 10.1038/nrm.2018.2. View

Yeo N, Chavez A, Lance-Byrne A, Chan Y, Menn D, Milanova D . An enhanced CRISPR repressor for targeted mammalian gene regulation. Nat Methods. 2018; 15(8):611-616. PMC: 6129399. DOI: 10.1038/s41592-018-0048-5. View

Mak A, Bradley P, Cernadas R, Bogdanove A, Stoddard B . The crystal structure of TAL effector PthXo1 bound to its DNA target. Science. 2012; 335(6069):716-9. PMC: 3427646. DOI: 10.1126/science.1216211. View

Swarts D, Mosterd C, van Passel M, Brouns S . CRISPR interference directs strand specific spacer acquisition. PLoS One. 2012; 7(4):e35888. PMC: 3338789. DOI: 10.1371/journal.pone.0035888. View

10.

Maeder M, Stefanidakis M, Wilson C, Baral R, Barrera L, Bounoutas G . Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat Med. 2019; 25(2):229-233. DOI: 10.1038/s41591-018-0327-9. View

11.

Hwang W, Fu Y, Reyon D, Maeder M, Tsai S, Sander J . Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol. 2013; 31(3):227-9. PMC: 3686313. DOI: 10.1038/nbt.2501. View

12.

Ishino Y, Krupovic M, Forterre P . History of CRISPR-Cas from Encounter with a Mysterious Repeated Sequence to Genome Editing Technology. J Bacteriol. 2018; 200(7). PMC: 5847661. DOI: 10.1128/JB.00580-17. View

13.

Yourik P, Fuchs R, Mabuchi M, Curcuru J, Robb G . Cas9 is a multiple-turnover enzyme. RNA. 2018; 25(1):35-44. PMC: 6298560. DOI: 10.1261/rna.067355.118. View

14.

Jansen R, van Embden J, Gaastra W, Schouls L . Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol. 2002; 43(6):1565-75. DOI: 10.1046/j.1365-2958.2002.02839.x. View

15.

Hirano S, Nishimasu H, Ishitani R, Nureki O . Structural Basis for the Altered PAM Specificities of Engineered CRISPR-Cas9. Mol Cell. 2016; 61(6):886-94. DOI: 10.1016/j.molcel.2016.02.018. View

16.

Mans R, van Rossum H, Wijsman M, Backx A, Kuijpers N, van den Broek M . CRISPR/Cas9: a molecular Swiss army knife for simultaneous introduction of multiple genetic modifications in Saccharomyces cerevisiae. FEMS Yeast Res. 2015; 15(2). PMC: 4399441. DOI: 10.1093/femsyr/fov004. View

17.

Song F, Stieger K . Optimizing the DNA Donor Template for Homology-Directed Repair of Double-Strand Breaks. Mol Ther Nucleic Acids. 2017; 7:53-60. PMC: 5363683. DOI: 10.1016/j.omtn.2017.02.006. View

18.

Prakash V, Moore M, Yanez-Munoz R . Current Progress in Therapeutic Gene Editing for Monogenic Diseases. Mol Ther. 2016; 24(3):465-74. PMC: 4786935. DOI: 10.1038/mt.2016.5. View

19.

Cradick T, Fine E, Antico C, Bao G . CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res. 2013; 41(20):9584-92. PMC: 3814385. DOI: 10.1093/nar/gkt714. View

20.

Komor A, Kim Y, Packer M, Zuris J, Liu D . Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016; 533(7603):420-4. PMC: 4873371. DOI: 10.1038/nature17946. View